When taking the trough level of Envarsus (tacrolimus), how much time plus or minus is allowed to get a good reading?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 13, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Timing for Envarsus Trough Level Collection

Trough levels of Envarsus (tacrolimus extended-release) should be drawn within 24 hours before the next dose, ideally as close to the next dose as possible (within 0-2 hours before administration) to obtain the most accurate reading.

Optimal Timing for Trough Level Collection

Tacrolimus is a calcineurin inhibitor (CNI) with a narrow therapeutic index that requires careful therapeutic drug monitoring to ensure optimal immunosuppression while minimizing toxicity. For Envarsus, which is a once-daily extended-release formulation of tacrolimus:

  • The KDIGO guidelines recommend monitoring tacrolimus using 12-hour trough (C0) levels 1
  • For extended-release formulations like Envarsus, the trough should be measured immediately before the next scheduled dose

Timing Window Considerations

While the KDIGO guidelines don't specify an exact time window for acceptable deviation from the 24-hour trough timing, clinical practice suggests:

  • Ideal timing: Within 0-2 hours before the next scheduled dose
  • Acceptable range: Within 24 hours before the next dose
  • Avoid: Taking levels after a dose has been administered or more than 24 hours after the previous dose

Pharmacokinetic Rationale

The specific timing is important due to Envarsus's unique pharmacokinetic properties:

  • Envarsus utilizes MeltDose technology that improves absorption of tacrolimus 2
  • It has a more stable concentration-time profile with reduced peak-trough fluctuations compared to immediate-release tacrolimus 3
  • The correlation between AUC0-24 and Cmin is variable, making precise trough timing important 3

Monitoring Frequency

The KDIGO guidelines suggest measuring CNI blood levels 1:

  • Every other day during the immediate post-operative period until target levels are reached
  • Whenever there is a change in medication or patient status that may affect blood levels
  • Whenever there is a decline in kidney function that may indicate nephrotoxicity or rejection

Practical Considerations

When converting from other tacrolimus formulations to Envarsus:

  • Dose reduction is typically required (33-43% lower than immediate-release formulations) 4
  • More intense monitoring is recommended during the conversion period
  • Population pharmacokinetic models suggest that early attainment of therapeutic trough levels can be improved with personalized dosing strategies 5

Common Pitfalls to Avoid

  • Inconsistent timing: Varying the time of blood collection can lead to misinterpretation of results
  • Post-dose sampling: Taking the sample after medication administration invalidates the trough reading
  • Formulation confusion: Mistakenly interchanging different tacrolimus formulations can lead to serious patient harm 3
  • Inadequate monitoring frequency: Especially during the early post-transplant period or after dose adjustments

Maintaining precise timing for trough level collection is essential for accurate therapeutic drug monitoring of Envarsus, which ultimately impacts graft survival and patient outcomes.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.